tiprankstipranks
Advertisement
Advertisement

XENE Stock Latest News

Biohaven downgraded to Underperform from Neutral at BofA
The FlyBiohaven downgraded to Underperform from Neutral at BofA
16d ago
BHVN
XENE
Xenon Shareholders Approve Directors, Pay and Incentive Plan
PremiumCompany Announcements
Xenon Shareholders Approve Directors, Pay and Incentive Plan
1M ago
8K
XENE
Xenon Pharmaceuticals price target raised to $82 from $80 at JPMorgan
PremiumThe Fly
Xenon Pharmaceuticals price target raised to $82 from $80 at JPMorgan
2M ago
XENE
Xenon Pharmaceuticals Signals Strong Momentum In Earnings
PremiumCompany Announcements
Xenon Pharmaceuticals Signals Strong Momentum In Earnings
2M ago
XENE
Xenon Pharmaceuticals price target raised to $80 from $77 at JPMorgan
PremiumThe Fly
Xenon Pharmaceuticals price target raised to $80 from $77 at JPMorgan
2M ago
XENE
Xenon Pharmaceuticals price target raised to $69 from $68 at Wells Fargo
PremiumThe FlyXenon Pharmaceuticals price target raised to $69 from $68 at Wells Fargo
2M ago
PRAX
XENE
Xenon Pharmaceuticals Maps Path After Standout XTOL-2
Premium
Company Announcements
Xenon Pharmaceuticals Maps Path After Standout XTOL-2
2M ago
XENE
Xenon Pharmaceuticals price target lowered to $78 from $80 at Needham
Premium
The Fly
Xenon Pharmaceuticals price target lowered to $78 from $80 at Needham
2M ago
XENE
Analyst Reaffirms Buy on Xenon, Citing Blockbuster Potential for Lead Epilepsy Candidate and Upside from Pipeline Programs
PremiumRatings
Analyst Reaffirms Buy on Xenon, Citing Blockbuster Potential for Lead Epilepsy Candidate and Upside from Pipeline Programs
2M ago
XENE
Xenon Highlights Positive Phase 3 Azetukalner Seizure Data
PremiumCompany Announcements
Xenon Highlights Positive Phase 3 Azetukalner Seizure Data
2M ago
8K
XENE
Xenon Pharmaceuticals reports Q1 EPS ($1.17), consensus ($1.20)
PremiumThe Fly
Xenon Pharmaceuticals reports Q1 EPS ($1.17), consensus ($1.20)
2M ago
XENE
XENE Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
XENE Upcoming Earnings Report: What to Expect?
2M ago
XENE
Xenon’s Azetukalner: Rapid, Durable Efficacy and Once‑Daily Convenience Underpin Buy Rating and Preferred Second‑Line Epilepsy Positioning
PremiumRatingsXenon’s Azetukalner: Rapid, Durable Efficacy and Once‑Daily Convenience Underpin Buy Rating and Preferred Second‑Line Epilepsy Positioning
3M ago
XENE
Xenon Pharmaceuticals presents data from Phase 3 X-TOLE2 study
Premium
The Fly
Xenon Pharmaceuticals presents data from Phase 3 X-TOLE2 study
3M ago
XENE
Xenon to Spotlight Neurology Pipeline at Series of 2026 Investor Conferences
Premium
Company Announcements
Xenon to Spotlight Neurology Pipeline at Series of 2026 Investor Conferences
3M ago
XENE
Xenon Expands 2025 Inducement Equity Incentive Plan
PremiumCompany Announcements
Xenon Expands 2025 Inducement Equity Incentive Plan
3M ago
8K
XENE
Xenon to Unveil Phase 3 Azetukalner Data and Pipeline Advances at 2026 AAN Meeting
PremiumCompany Announcements
Xenon to Unveil Phase 3 Azetukalner Data and Pipeline Advances at 2026 AAN Meeting
3M ago
XENE
Xenon Pharmaceuticals price target lowered to $63 from $64 at Wedbush
PremiumThe Fly
Xenon Pharmaceuticals price target lowered to $63 from $64 at Wedbush
4M ago
XENE
Xenon Sets Date for 2026 Annual Shareholder Meeting
PremiumCompany Announcements
Xenon Sets Date for 2026 Annual Shareholder Meeting
4M ago
8K
XENE
Xenon’s X-TOLE2 Trial Completion Puts XEN1101 in Focus for Epilepsy Investors
PremiumCompany AnnouncementsXenon’s X-TOLE2 Trial Completion Puts XEN1101 in Focus for Epilepsy Investors
4M ago
XENE
Xenon Strengthens Balance Sheet With Major Equity Offering
Premium
Company Announcements
Xenon Strengthens Balance Sheet With Major Equity Offering
4M ago
8K
XENE
Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00
Premium
The Fly
Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00
4M ago
XENE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >